We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients Product Name:99% up by HPLC, USP, EP Zidovudine 30516-87-1 CAS No.:30516-87-1 Standard:USP, BP, EP, JP, In-house Standards Price(USD):Negotiable Company:Sinoway Industrial Co.Ltd.
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East
Monthly Production Capacity: 1000kg
Packaging Information: 25kg/drum 1kg/bottle
Delivery Lead Time: 7 days after payment
Sample Provided: yes
Payment Terms: L/L
Product Information
Product name
Zidovudine
CAS No.
30516-87-1
Molecular Formula
C10H13N5O5
Molecular Weight
283.24
Quality Standard
99% up, USP,EP
Appearance
White powder
COA of Zidovudine
TEST
STANDARD
RESULT
Appearance:
White powder
Complies
Loss on drying
≤ 6.0%
3.83%
Heavy metals
< 10ppm
Complies
As
≤ 3.0 ppm
Complies
Pb
≤ 3.0 ppm
Complies
Cd
≤ 0.5 ppm
Complies
Microbiology
Total plate count
< 1000 cfu/g
326 cfu/g
Yeast & Mold
< 100 cfu/g
28 cfu/g
E. Coli
Negative
Complies
S. Aureus
Negative
Complies
Salmonella
Negative
Complies
Assay
995-101%
99,。5%
Conclusion
Conforms with USP standard
Usage
Function of Zidovudine
Zidovudine is an antiviral drug used in the treatment of patients with AIDS or AIDS-related syndromes and immunodeficiency virus (HIV) infection. It is highly active against retroviruses including human immunodeficiency virus (HIV) in vitro. In virus-infected cells, it is phosphorylated by cellular thymidine kinase to zidovudine triphosphate, which can selectively inhibit HIV reverse transcriptase, leading to the termination of HIV chain synthesis and preventing HIV replication. On March 19, 1987, the US Food and Drug Administration approved the drug for marketing. Zidovudine is the world's first anti-AIDS drug approved by the US FDA.
Twenty years of qualification
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
